(Q42961046)

11 November 2017

title

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study (English)

1 reference

11 November 2017

1 reference

11

David A Flockhart

1 reference

11 November 2017

6

Zeruesenay Desta

1 reference

11 November 2017

Rolf P Kreutz

1

1 reference

11 November 2017

Eric J Stanek

2

1 reference

11 November 2017

Ronald Aubert

3

1 reference

11 November 2017

Jianying Yao

4

1 reference

11 November 2017

Jeffrey A Breall

5

1 reference

11 November 2017

Todd C Skaar

7

1 reference

11 November 2017

J Russell Teagarden

8

1 reference

11 November 2017

Felix W Frueh

9

1 reference

11 November 2017

Robert S Epstein

10

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

30

1 reference

11 November 2017

issue

8

1 reference

11 November 2017

page(s)

787-796

1 reference

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

The assessment of refill compliance using pharmacy records: methods, validity, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.8.787

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.8.787

1 reference

11 November 2017

1 reference